INDIAGLYCO
1 call
Concalls & earnings callsIndia Glycols Limited
Every summarised call, newest first. Latest is Q1 FY27, held 14 Aug 2026.
Latest quarter
Q1 FY27 snapshot
Open full brief →The company posted strong double-digit revenue and profit growth across its diversified portfolio, led by a record EBITDA quarter and a strategic demerger plan approved by the NCLT.
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Net Revenue | ₹1,130 Cr | 9% | |
| EBITDA | ₹170 Cr | 13% | |
| PAT | Not Stated | 32% | |
| EBITDA Margin | 15.0% | — |
Latest guidance
- Aspiration: IGL Spirits to deliver EBITDA in excess of INR500 crores for FY27 and target >INR1,000 crores EBITDA in 4-5 years.
- Aspiration: India Glycols (Chemicals) to deliver EBITDA of ~INR400 crores and be an INR2,500 crores business in 4-5 years.
- Aspiration: Ennature Bio Pharma to achieve EBITDA of INR130-150 crores in the next 4-5 years.
Said on the Q1 FY27 call.
Filed results
Reported quarterly history
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹2,424.01 Cr+14.4% YoY+13.1% QoQ | ₹56.81 Cr+36.5% YoY+14.3% QoQ | ₹18.35+36.4% YoY+14.3% QoQ |
| Q2 FY25 | ₹2,143.71 Cr+14.6% YoY-6.1% QoQ | ₹49.71 Cr+30.8% YoY-17.7% QoQ | ₹16.06+30.9% YoY-17.6% QoQ |
| Q1 FY25 | ₹2,282.58 Cr+20.5% YoY+11.9% QoQ | ₹60.38 Cr+18.1% YoY+43% QoQ | ₹19.50+18% YoY+43.1% QoQ |
| Q4 FY24 | ₹2,039.08 Cr+26.2% YoY-3.8% QoQ | ₹42.21 Cr+5.9% YoY+1.4% QoQ | ₹13.63+5.9% YoY+1.3% QoQ |
| Q3 FY24 | ₹2,118.94 Cr+39% YoY+13.3% QoQ | ₹41.63 Cr-16.8% YoY+9.5% QoQ | ₹13.45-16.8% YoY+9.6% QoQ |
Call history
- Q1 FY27Positive tone
The company posted strong double-digit revenue and profit growth across its diversified portfolio, led by a record EBITDA quarter and a strategic demerger plan approved by the NCLT.
- Net Revenue
- ₹1,130 Cr9%
- EBITDA
- ₹170 Cr13%